Tests XmAb819 safety in adults with advanced kidney cancer
Tests XmAb819 for safety in adults with advanced clear cell kidney cancer.
Plain-language title generated from the registry record
Registry title: Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Key facts
- Where
- Leuven, BelgiumSee the site
- Phase
- Phase 1
Where in Belgium
- UZ LeuvenLeuven, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xencor, Inc.
- Trial code
- NCT05433142EU 2024-513619-28-00
- Record updated
- 3 August 2026
- Original description
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).Read full original descriptionShow less
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
Inclusion: Subjects must have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) as assessed by the local site investigator. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions; Subjects who have relapsed and refractory ccRCC, pRCC, NSCLC, and CRC with evidence of disease progression on standard-of-care therapies; ECOG performance status of 0 or 1; All subjects must have adequate tumor sample available (slides or archival FFPE blocks).
Exclusion: Prior treatment with an investigational anti-ENPP3/CD203c therapy; Systemic antineoplastic therapy within 5 half-lives on the first dose of study treatment; Failure to recover from any clinically significant toxicity related to previous anticancer treatment; Have known active central nervous system metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable,; Evidence of any serious infection requiring IV anti-infective treatment within 14 days prior to the first dose of study drug; History of serious allergic or anaphylactic/hypersensitivity reaction to monoclonal antibody therapy; Active known autoimmune disease (except that subjects are permitted to enroll if they have vitiligo; type 1 diabetes mellitus; residual hypothyroidism due to an autoimmune condition that is treatable with hormone replacement therapy only; psoriasis, atopic dermatitis, or another autoimmune skin condition that is managed without systemic therapy; or arthritis that is managed without systemic therapy beyond oral acetaminophen and nonsteroidal anti-inflammatory drugs); Have a known additional malignancy that is progressing or has required active treatment within the past 2 years.